Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.72 |
| ▸ | CCND1 | P24385 | 7/20 | 0.72 |
| ▸ | CCND3 | P30281 | 5/20 | 0.72 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.72 |
| ▸ | CDK1 | P06493 | 3/20 | 0.72 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.72 |
| ▸ | CDK2 | P24941 | 3/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.72 |
| ▸ | ATR | Q13535 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2129207 | 0.88 | CDK4 (0.78) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL111565 | 0.87 | CDK4 (0.71) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL111295 | 0.87 | CDK4 (0.75) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL3721802 | 0.86 | CDK4 (0.76) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL109487 | 0.85 | CDK4 (0.73) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL111810 | 0.84 | CDK4 (0.83) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL114340 | 0.84 | CDK4 (0.84) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL111263 | 0.84 | CDK4 (0.68) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL111954 | 0.84 | CDK4 (1.00) | CDK4CCND1CCND3CDK6CDK1 | |
| SCHEMBL112578 | 0.84 | CDK4 (0.74) | CDK4CCND1CCND3CDK6CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | claimed |
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2424843-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | Novartis AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | CDK4 13/4885CCND1 30/4885CCND3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.